RADIATE-VT VAR-2022-01
Brief description of study
The principal hypothesis of the Varian CRA randomized trial is that Varian CRA is safer and provides at least equivalent efficacy compared to repeat CA for patients with high-risk refractory VT who have experienced VT recurrence after CA and are candidates for additional CA.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: - 99 Years
-
Gender: All
TBD
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
